DEXCOM INC's ticker is and the CUSIP is 252131AH0. A total of 32 filers reported holding DEXCOM INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 1.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,040 | -99.1% | 12,000 | -98.6% | 0.00% | -100.0% |
| Q2 2023 | $2,665,209 | +10.6% | 852,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $2,410,155 | -29.5% | 852,000 | -31.2% | 0.00% | 0.0% |
| Q4 2022 | $3,418,302 | +28.3% | 1,239,000 | -7.5% | 0.00% | 0.0% |
| Q3 2022 | $2,664,000 | +32.2% | 1,339,000 | +23.0% | 0.00% | 0.0% |
| Q2 2022 | $2,015,000 | -37.8% | 1,089,000 | +4.8% | 0.00% | 0.0% |
| Q1 2022 | $3,237,000 | +20.6% | 1,039,000 | +26.4% | 0.00% | 0.0% |
| Q4 2021 | $2,685,000 | +11.8% | 822,000 | +13.9% | 0.00% | 0.0% |
| Q3 2021 | $2,401,000 | -79.6% | 722,000 | -84.1% | 0.00% | -66.7% |
| Q2 2021 | $11,769,000 | +65.3% | 4,529,000 | +40.2% | 0.00% | +50.0% |
| Q1 2021 | $7,118,000 | +156.9% | 3,230,000 | +165.0% | 0.00% | +100.0% |
| Q4 2020 | $2,771,000 | -29.7% | 1,219,000 | -21.9% | 0.00% | 0.0% |
| Q3 2020 | $3,941,000 | -3.2% | 1,560,000 | -4.9% | 0.00% | 0.0% |
| Q2 2020 | $4,072,000 | +41.8% | 1,641,000 | -0.1% | 0.00% | 0.0% |
| Q1 2020 | $2,872,000 | – | 1,643,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Elequin Capital, LP | 11,771,000 | $26,632,270 | 5.17% |
| Calamos Advisors LLC | 30,006,000 | $67,881,974 | 0.35% |
| CAPSTONE INVESTMENT ADVISORS, LLC | 5,000,000 | $11,302,500 | 0.05% |
| D. E. Shaw & Co., Inc. | 10,000,000 | $23,351,070 | 0.02% |
| UBS ASSET MANAGEMENT AMERICAS LLC | 23,000,000 | $52,692,310 | 0.02% |
| BNP PARIBAS FINANCIAL MARKETS | 1,035,000 | $2,337,030 | 0.00% |
| LOOMIS SAYLES & CO L P | 9,739 | $909 | 0.00% |
| MORGAN STANLEY | 2,500,000 | $5,648,750 | 0.00% |
| FMR LLC | 6,019,000 | $13,590,902 | 0.00% |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 200,000 | $451,600 | 0.00% |